Ikklikkja hawn jekk dan huwa l-istqarrija għall-istampa tiegħek!

Losartan Medikazzjoni ta 'Pressjoni Għolja Issa Mfakkra

Written by editur

Mint Pharmaceuticals Inc. qed tfakkar il-lottijiet kollha tal-pilloli tal-losartan bi preskrizzjoni tagħha, f'qawwiet ta' 50 mg u 100 mg, wara li t-testijiet sabu impurità azido (5-(4′-((5-(azidometil)-2-butyl-4-chloro) -1H imidazol-1-yl)methyl)-[1,1′-biphenyl]-2-yl)-1H tetrazole) 'l fuq mil-limitu aċċettabbli. L-espożizzjoni fit-tul għall-impurità f'livelli ogħla minn dak li hu meqjus bħala sigur jista' potenzjalment iżid ir-riskju tal-kanċer.

Stampa Friendly, PDF & Email

Jekk jogħġbok ara l-konsulenza sħiħa għal aktar informazzjoni, inkluż x'għandhom jagħmlu l-Kanadiżi u x-xogħol tas-Saħħa Kanada biex tindirizza l-kwistjoni tal-impuritajiet azido misjuba f'ċerti mediċini.

prodottkumpanijaDINLottSkadenza
PILLOLI MINT-LOSARTAN/HCTZ 50/12.5 mgMint Pharmaceuticals Inc.023896572005006959April 2023
PILLOLI MINT-LOSARTAN/HCTZ 50/12.5 mgMint Pharmaceuticals Inc.023896572005006960April 2023
PILLOLI MINT-LOSARTAN/HCTZ 50/12.5 mgMint Pharmaceuticals Inc.023896572005006961April 2023
PILLOLI MINT-LOSARTAN/HCTZ 50/12.5 mgMint Pharmaceuticals Inc.023896572005006962April 2023
PILLOLI MINT-LOSARTAN/HCTZ 50/12.5 mgMint Pharmaceuticals Inc.023896572005006963April 2023
PILLOLI MINT-LOSARTAN/HCTZ 50/12.5 mgMint Pharmaceuticals Inc.023896572005011154ġunju 2023
PILLOLI MINT-LOSARTAN/HCTZ 50/12.5 mgMint Pharmaceuticals Inc.023896572005011156ġunju 2023
PILLOLI MINT-LOSARTAN/HCTZ 100/12.5 mgMint Pharmaceuticals Inc.023896652005006807April 2022
PILLOLI MINT-LOSARTAN/HCTZ 100/12.5 mgMint Pharmaceuticals Inc.023896652005006808April 2022
PILLOLI MINT-LOSARTAN/HCTZ 100/12.5 mgMint Pharmaceuticals Inc.023896652005006809April 2022
PILLOLI MINT-LOSARTAN/HCTZ 100/12.5 mgMint Pharmaceuticals Inc.023896652005006810April 2022
PILLOLI MINT-LOSARTAN/HCTZ 100/12.5 mg Mint Pharmaceuticals Inc.023896652105002149diċembru 2022
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLIMint Pharmaceuticals Inc.023896731805012687ottubru 2021
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLIMint Pharmaceuticals Inc.023896731805012688ottubru 2021
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLIMint Pharmaceuticals Inc.023896731805012689ottubru 2021
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLIMint Pharmaceuticals Inc.023896731805012792ottubru 2021
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLIMint Pharmaceuticals Inc.023896731905001010diċembru 2021
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLI Mint Pharmaceuticals Inc.023896731905001011diċembru 2021
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLIMint Pharmaceuticals Inc.023896732005006947April 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLIMint Pharmaceuticals Inc.023896732005006949April 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLIMint Pharmaceuticals Inc.023896732005006950April 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLIMint Pharmaceuticals Inc.023896732005006951April 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLI Mint Pharmaceuticals Inc.023896732005007297April 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLIMint Pharmaceuticals Inc.023896732005007298April 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLIMint Pharmaceuticals Inc.023896732005013776awissu 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg PILLOLIMint Pharmaceuticals Inc.023896732105002150diċembru 2023
Stampa Friendly, PDF & Email

Dwar l-Awtur

editur

L-editur kap huwa Linda Hohnholz.

Kumment